Clinical trials: SARS-CoV-2 Virus Infection
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
A Longitudinal Study of COVID-19 Sequelae and Immunity
Background: COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract. Some people who get COVID-19 have only mild symptoms.
- Trial name
- NCT04411147
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, Diabete Mellitus
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients…
- Trial name
- NCT05867017
- Testing
- Measure of physiologic parameters
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
COVID-19, Corona Virus Infection
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Agent Name and Study Duration ArtemiC is a medical spray comprised of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (=Boswellia) (15 mg/ml) and vitamin C (60 mg/ml) in micellar formulation for spray administration.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2, Coronavirus
- Trial name
- NCT04382040
- Testing
- ArtemiC
- Where
- 4 sites in India, Israel
- Volunteers
- 50 people
- Sponsor
- MGC Pharmaceuticals d.o.o
Covid19, Sars-CoV-2 Infection
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date.
- Conditions
- Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
- Trial name
- NCT04715360
- Testing
- autologous activated platelet-rich plasma, Avigan
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Hayandra Peduli Foundation
COVID-19, SARS-CoV 2
Convalescent Plasma for the Treatment of Patients With COVID-19
This expanded access program will provide access to COVID-19 convalescent plasma 150 or more individuals with moderate to severe or life-threatening manifestations of COVID-19, or documented to be at high risk of developing such…
- Trial name
- NCT04372368
- Testing
- COVID-19 Convalescent Plasma
- Where
- 6 sites in United States
- Sponsor
- University of Colorado, Denver
Sars-CoV2, ARDS
Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection
The purpose of this study is to evaluate if a postural recruitment maneuver (PRM) improves the aeration and distribution of lung ventilation in patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19…
- Trial name
- NCT04475068
- Testing
- Lateral Position (left and right lateral decubitus)
- Where
- Peru
- Volunteers
- 15 people
- Sponsor
- Hospital Nacional Edgardo Rebagliati Martins
COVID-19
Antibody Responses in Contacts of COVID-19 Patients
After several cases of pneumonia with an unfamiliar etiology were observed at the end of 2019, the National Health Commission of China released more details about the epidemic in early 2020.
- Trial name
- NCT04444310
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Influenza, SARS-CoV-2 (COVID-19) Infection
Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
The purpose of this study is to evaluate the virus-specific immune response in people who are symptomatic with confirmed influenza or COVID-19.
- Conditions
- Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
- Trial name
- WU 437 (NCT06848309)
- Testing
- Bronchoscopy
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
COVID-19
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.
- Trial name
- NCT04432298
- Testing
- Pamrevlumab
- Where
- 4 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Kyntra Bio
Covid19
PCR Cycle Threshold Values and COVID-19 Outcomes
This is a retrospective observational study. The study will use high quality, reliable data that has already been collected for the ISARIC 4C COVID-19 study in order to analyse the relation between predictor variables (laboratory…
- Trial name
- NCT04651413
- Testing
- PCR Value
- Where
- United Kingdom
- Volunteers
- 934 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Covid19
Correlation Between Cycle Threshold (Ct) Values in COVID-19, Health Status and Laboratory Biomarkers in the Population of Medellin- Colombia Evaluated in a Specialized Laboratory.
This study will evaluate the correlation between the symptomaticity, Ct value, laboratory biomarkers associated to COVID-19 and the disease progression in hospitalized patients and outpatients with SARS-CoV2 infection diagnosed…
- Trial name
- NCT05067920
- Testing
- Levels of SARS-COV-2 antibodies, rRT-PCR SARS-Cov-2, Hematological and immunological biomarkers
- Where
- Colombia
- Volunteers
- 120 people
- Sponsor
- Universidad de Antioquia
COVID-19, Hypoxemic Respiratory Failure
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
Coronavirus disease (COVID-19) can result in severe hypoxemic respiratory failure that ultimately may require invasive mechanical ventilation in the Intensive Care Unit (ICU).
- Trial name
- NORMO2 (NCT06033560)
- Testing
- High flow nasal oxygen (HFNO, more than 15 L/min)
- Where
- Netherlands
- Volunteers
- 6,000 people
- Sponsor
- Amsterdam UMC, location VUmc
Covid19
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19 participants who were in cytokine release syndrome and there was also a control group who received steroids(RECOVERY TRIAL wasn't published or…
- Trial name
- NCT04730323
- Testing
- Tocilizumab
- Where
- Pakistan
- Volunteers
- 93 people
- Sponsor
- FMH College of Medicine and Dentistry
COVID-19
Dendritic Cell Vaccine to Prevent COVID-19
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
- Trial name
- NCT04685603
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Indonesia-MoH
Post Acute COVID-19 Syndrome, Long COVID
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
This is a randomized (1:1) , placebo-controlled phase II study to evaluate the safety, tolerability and efficacy of S-1226 in Post-COVID-19 subjects (n≤48) with persistent respiratory symptoms.
- Conditions
- Post Acute COVID-19 Syndrome, Long COVID, COVID-19 Respiratory Infection
- Trial name
- NCT04949386
- Testing
- S-1226 (8%)
- Volunteers
- 48 people
- Sponsor
- SolAeroMed Inc.
COVID-19
Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection
The risk for the development of complications from COVID-19 occurs mainly in patients over 65 years of age, with obesity, arterial hypertension, chronic lung diseases and immunosuppression states.
- Trial name
- NCT05089305
- Testing
- Ozone plasma
- Where
- 2 sites in Mexico
- Volunteers
- 35 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
COVID-19 Pandemic
External Validation of the 4C Mortality Score for Hospitalised Patients With COVID-19 in a Tunisian Cohort
Risk prediction scores are important tools to support clinical decision-making for patients with coronavirus disease (COVID-19).
- Trial name
- 4C (NCT05498324)
- Where
- Tunisia
- Volunteers
- 1,500 people
- Sponsor
- University of Monastir
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.
Phase IIb clinical trial to assess the Immunogenicity and Safety of a HIPRA's Candidate Booster vaccination (PHH-1V) in adults fully vaccinated with the adenovirus vaccine Vaxevria against COVID-19.
- Trial name
- NCT05305573
- Testing
- COVID-19 Vaccine HIPRA 40 ug/dose, Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
- Where
- 7 sites in Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U